Recurrence After Treatment of Nonmelanoma Skin Cancer

Abstract

To determine long-term tumor recurrence rates after treatment of primary nonmelanoma skin cancer (NMSC). Data are currently insufficient to permit evidence-based choices among treatments for NMSC.Design: Prospective study of an inception cohort observed for a median of 6.6 years after treatment.Setting: Dermatology clinic at a Veterans Affairs hospital. Care was provided by dermatology resident or attending physicians.Patients: Consecutive sample of all 495 patients with 616 primary NMSCs diagnosed in 1999 and 2000 and treated with electrodessication and curettage (ED&C), excision, or Mohs surgery. Follow-up was available for 608 tumors (99%).Main Outcome Measure: Tumor recurrence, deter-mined by medical record review, with validation by clinical examination. Results:The mean age at diagnosis was 71 years; 97% were men. Overall, 127 tumors were treated with ED&C (20.9%); 309 with excision (50.8%); and 172 with Mohs surgery (28.3%). Over the course of the study, 21 tumors recurred (3.5% [95% confidence interval (CI), 2.2%-5.2%]): 2 after ED&C (1.6% [95% CI, 0.2%-5.6%]), 13 after excision (4.2% [95% CI, 2.2%-7.1%]), and 6 after Mohs surgery (3.5% [95% CI, 1.3%-7.4%]).Conclusions: Recurrence of primary NMSC after treatment occurred in less than 5% of tumors. The recurrence rate after ED&C was lower than expected, and the recurrence rate after Mohs surgery was higher than expected. These findings may be related to the risk for recurrence in the treatment groups.

Non-melanoma Skin Cancer – a Clinicopathological Study of Patients with Basal Cell Carcinoma and Squamous Cell Carcinoma

“…In both subroups, men were more In the present study, 4.1% of all BCC lesions and 1.8% of all SCC lesions locally recurred dur ing the 7.5-years period, roughly agree ing with the observations from previous studies [27][28][29][30]. However, as they represented only microscopically verified cases, a certain number of tumor relapses could have been subsequently treated non-invasively without histopathologic examination.…”

“…The recurrence rate depends on several factors, such as anatomic location and size of lesions, histologic subtypes of tumors, chosen therapeutic modality and resection margin status after total surgical ex cision. According to literature data, local recurrence rates range between 3.4 and 4.3% for BCCs [27,28] and between 2 and 3.6% for SCCs [27,29,30]. These values are similar and even some authors [27] did Regard ing gender, we found that SCCs more frequently occurred in men (68.2%) than women (31.8%), justify ing data from many previous reports [1,11,12,17,18].…”

“…According to literature data, local recurrence rates range between 3.4 and 4.3% for BCCs [27,28] and between 2 and 3.6% for SCCs [27,29,30]. These values are similar and even some authors [27] did Regard ing gender, we found that SCCs more frequently occurred in men (68.2%) than women (31.8%), justify ing data from many previous reports [1,11,12,17,18]. In BCC, however, the results regard ing gender prevalence are much more controversial.…”

Current Advances in the Treatment of Basal Cell Carcinoma

“…Standart eksizyon 5 yıllık rekürrens oranlarının %2-10 arasında değiştiği bütün primer BHK olgularda etkili tedavi seçeneğidir [20][21][22] . Genel kabul gören güvenli cerrahi sınır 3-5 mm.…”

Combined reflectance confocal microscopy-optical coherence tomography for delineation of basal cell carcinoma margins: anex vivostudy

“…8,9 Currently, an estimated 1.5 million surgeries are performed every year for nonmelanoma skin cancers (both BCCs and squamous cell carcinomas), with treatment costs of about $2 billion. 10 Mohs surgery is labor-intensive, time-consuming, and expensive.…”